Last reviewed · How we verify

PD-0332991 — Competitive Intelligence Brief

PD-0332991 (pd-0332991) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-0332991, 125mg, 3 cycles. Area: Oncology.

discontinued PD-0332991, 125mg, 3 cycles Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2 Oncology Live · refreshed every 30 min

Target snapshot

PD-0332991 (pd-0332991) — Pfizer Inc.. PD-0332991, 125mg, 3 cycles

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PD-0332991 TARGET pd-0332991 Pfizer Inc. discontinued PD-0332991, 125mg, 3 cycles Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-0332991, 125mg, 3 cycles class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PD-0332991 — Competitive Intelligence Brief. https://druglandscape.com/ci/pd-0332991. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: